BAM
CLDX icon

Byrne Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Byrne Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-86
Closed -$2K – 549
2023
Q3 		$2K Hold
86
– – ﹤0.01% 471
2023
Q2 		$3K Hold
86
– – ﹤0.01% 502
2023
Q1 		$3K Hold
86
– – ﹤0.01% 494
2022
Q4 		$3.83K Hold
86
– – ﹤0.01% 455
2022
Q3 		$2K Hold
86
– – ﹤0.01% 465
2022
Q2 		$2K Hold
86
– – ﹤0.01% 484
2022
Q1 		$3K Hold
86
– – ﹤0.01% 480
2021
Q4 		$3K Buy
+86
New +$3.75K ﹤0.01% 483

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Byrne Asset Management's CLDX Position: Q4 2023 in Review

Byrne Asset Management sold out of Celldex Therapeutics (CLDX) in Q4 2023, closing a stake of 86 shares — an estimated $2K sold.

Byrne Asset Management first reported a position in CLDX in Q4 2021 and held it in 8 quarters. The position peaked at $3.83K in Q4 2022. 164 funds tracked by Wall St. Rank hold CLDX as of Q4 2023.

  • Byrne Asset Management reported no remaining Celldex Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Byrne Asset Management sold 86 Celldex Therapeutics shares in Q4 2023, an estimated $2K.
  • Byrne Asset Management first reported a position in Celldex Therapeutics in Q4 2021 and held it in 8 quarters.
  • Byrne Asset Management's Celldex Therapeutics position peaked at $3.83K in Q4 2022.
  • 164 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2023.

Based on Byrne Asset Management's 13F filing for Q4 2023, filed 29 Jan 2024.